

# THE CAMPBELL FOUNDATION

GRANT HISTORY  
1995-Present

Scroll down within document to read



YEAR	AMOUNT	GRANT RECIPIENT	GRANT TITLE
------	--------	-----------------	-------------

2022	\$50,000	Harvard	<a href="#">Characterizing the HIV-1 Reservoir Landscape in HIV-1 Clade Infected Adolescents &amp; Young Adults from Botswana</a>
2022	\$90,000	UCLA	<a href="#">Escape from HIV-Specific Chimeric Antigen Receptors</a>
2021	\$80,000	The Wistar Institute	<a href="#">“Role of Intestinal Barrier Integrity and Antibody Glycosylation in Long-COVID During HIV-infection”</a>
2021	\$85,000	HIV-Assist	<a href="#">Improving prevision HIV care through a mobile device application for evidence-based decision and education support for antiretroviral selection</a>
2021	\$90,000	Weill Cornell Medicine Clinical Directors Network	<a href="#">Investigating the Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) for Measures of Cardiovascular Disease and Neurologic Outcomes in People Living with HIV-1</a>
2020	\$80,00	University of Miami Miller School	<a href="#">Anti-HIV Antibodies for Effective &amp; durable Adeno-Associated Virus (AAV) Delivery</a>
2020	\$85,000	Burnet Institute	<a href="#">Enhancing the Vaginal Environment and Microbiota (EVE-M) to Prevent HIV Transmission</a>
2020	\$80,000	Tel Aviv University	<a href="#">Using the Germline Precursors of the Anti-HIV Broadly Neutralizing Antibody BG18 as a Template for HIV Vaccine Design</a>
2018	\$75,000	McGovern Medical School at UTHealth	<a href="#">Mechanisms of Fibrosis in Chronic Treated HIV Infection</a>

2018	\$88,000	Tufts University School of Medicine	<a href="#">Linking Structural Dynamics of HIV-1 Env to Correlates of Immunoprotection in the RV144 Vaccine Trial</a>
2018	\$75,000	Stanford University School of Medicine	<a href="#">A Combined Drug Resistance and Virus Load Point of Care Assay</a>
2018	\$100,000	The Wistar Institute	<a href="#">Role of Host Glycosylation in the Galectin-9-Mediated Reversal of HIV Latency</a>
2017	\$80,000	The Ohio State University College of Medicine	<a href="#">Grant to Develop Gene Editing Tool to Destroy Latent HIV Cells in Lymph Nodes</a>
2017	\$10,000	The Montrose Center	<a href="#">Hurricane Harvey Emergency Grant</a>
2017	\$10,000	AIDS Foundation Houston	<a href="#">Hurricane Harvey Emergency Grant</a>
2017	\$75,000	David Geffen School of Medicine at UCLA	<a href="#">Novel Therapies for HIV-Related Aging of the Immune System</a>
2017	\$25,000	Miami Center for AIDS Research University of Miami Miller School of Medicine	<a href="#">Local Research Grant Initiative</a>
2017	\$25,000	Broward Health Comprehensive Care Center	
2017	\$25,000	Herbert Wertheim College of Medicine at FIU	<a href="#">Local Research Grant Initiative</a>
			<a href="#">Local Research Grant Initiative</a>

2017	\$85,000	<a href="#">Indiana University School of Medicine</a>	<a href="#">Probenecid-Boosted Tenofovir: A New Strategy for On-Demand HIV Pre-Exposure Prophylaxis</a>
2016	\$77,495	Massachusetts General Hospital	<a href="#">Brain inflammation and cognitive decline in HIV patients with dysbiotic microbiome</a>
2016	\$79,151	Scripps Research Institute, Jupiter, FL	<a href="#">Targeting HIV-1 Latent Infection with a Potent Tat Inhibitor</a>
2016	\$80,000	Northwestern University	<a href="#">Controlling HIV Release from Cells with First-in-Class Drugs Targeting Virus Budding</a>
2016	\$75,000	Drexel University College of Medicine	<a href="#">Long-Acting Formulation for the Systemic Delivery of HIV-1 Inactivators Using Metamorphic T-Cell-like Liposomes</a>
2015	\$60,000	Columbia University Medical Center	<a href="#">Arterial Wall Infection by HIV as a Trigger for Arterial Wall Inflammation</a>
2015	\$48,900	<a href="#">Case Western/Rainbow Babies Hospital</a>	<a href="#">Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV-infected Children and Healthy Controls</a>
2015	\$30,000	Children's Diagnostic & Treatment Center	<a href="#">Local Research Grant Initiative</a>
2015	\$30,000	University of Miami Miller School of Medicine	<a href="#">Local Research Grant Initiative</a>
2015	\$30,000	Florida Atlantic University Charles Schmidt College of Medicine	<a href="#">Local Research Grant Initiative</a>
2015	\$100,000	Ben-Gurion University, Israel	<a href="#">Efficacy of Tenofovir Delivered to the Brain by Novel Nanovesicles in a Neuro-HIV Mouse Model</a>
2014	\$50,000	amfAR	<a href="#">Countdown to a Cure Matching Grant Program</a>
2014	\$85,000	Children's Hospital Boston at Harvard	<a href="#">Novel Mechanisms Regulating HIV-1 Latency in HIV/TB Co-Infection</a>

2014	\$79,375	The George Washington University	Defining the Unique Biomarkers of Latently Infected T-Cells
2014	\$88,415	Johns Hopkins University Medical School	Pharmacokinetics and Pharmacodynamics of the Etonogestrel Implant When Co-administered With Efavirenz
2014	\$79,954	VA Medical Center, Vermont	Blocking CXCL9 to Improve Anti-HIV Potency of Tenofovir
2013	\$100,000	Mount Sinai School of Medicine	Simultaneous Disruption of Latency & Immune Enhancement by Poly ICLC During HIV-1 Infection
2013	\$88,000	Univ. of Pittsburgh	MicroRNAs as Biomarkers for HIV-1 Associated Neurocognitive Impairment & Dementia: Development of a Sensitive Diagnostic Tool
2013	\$50,000	R.A.I.N., Oklahoma City	Emergency Relief Grant
2013	\$86,431	Univ. of California, Davis	Pre-Selective Anti-HIV Vectors for Improved HIV Stem Cell Gene Therapy
2012	\$73,047	Washington University	Topical Fusogenic Nanosnares for HIV Prophylaxis
2012	\$82,500	UCSF	Restriction of HIV Replication
2012	\$100,000	Mount Sinai School of Medicine	Isolation of Novel Prothymosin-a Variants with Potent Anti-HIV & Interferon Inducing Activities
2012	\$86,130	Ben-Gurion University	Delivery of Tenofovir to the Brain by Novel Nanovesicles for the Treatment of Neuro-HIV
2012	\$78,479	University of Minnesota	Investigation of a Novel Chemotherapy to Target HIV Infectivity
2011	\$32,919	Univ. of Miami	Host Apolipoprotein E Affects Development of HIV-Ass'd Neurological Disease
2011	\$25,000	AIDS Alabama	Emergency Relief Grant

2011	\$60,000	Pennsylvania State University	Alternative Therapies to Combat HIV: Targeting Tat by Natural Products
2011	\$77,000	UC Davis	Role of the MSS1 Protein in HIV-1/SIV Replication & Pathogenesis
2011	\$85,000	UCLA	Telmisartan and Flow-Mediated Dilatation in Older HIV+ Patients at Risk for Cardio Disease
2011	\$20,000	UCLA	Assessing Cardio Risk & Impact of Hep C Treatment on Cardio Risk Biomarkers
2011	\$50,000	AMFAR	ARCHE Program Grant
2010	\$55,000	Washington University, St. Louis	Dipeptidyl Peptidase-4 Inhibition & Immune Function in HIV
2010	\$44,000	Univ. of Southern California	Identification of Novel Cellular Cofactors of HIV
2010	\$70,000	Univ. of Vermont	Targeting Human Proteins for Treatment of Cryptosporidiosis
2010	\$28,435	Dartmouth-Hitchcock Medical Center	Semen Protects Target CD4+ Cells from HIV Infection
2010	\$51,953	UC Davis	Flash-Heating Breast Milk to Decrease Morbidity, Improve Growth, & Reduce HIV Transmission in HIV-Exposed Infants
2010	\$64,327	Rush Univ. Medical Center	Acupuncture to Reduce HIV-Associated Inflammation
2010	\$71,815	UC San Diego	Prosp. Study of Vitamin D on Cutaneous Innate Immune Responses in HIV+ Subjects w/ and w/out CA-MRSA
2009	\$40,000	Burnet Institute, Australia	Adaptive Changes in HIV Subtype C Envelope Glycoproteins Contributing to Pathogenicity
2009	\$45,047	Brigham & Women's Hospital	Detection of Minority HIV-1 Variants by Deep Sequencing

2009	\$35,000	Univ. of Minnesota	Enabling Lethal Restriction of HIV-1 by Human APOBEC3G
2009	\$88,000	Univ. of California, San Francisco	Importance of Plasmacytoid Dendritic Cells in HIV Infection
2008	\$96,381	New York Blood Center	Developing Cell Penetrating Peptides as HIV-1 Assembly Inhibitors
2008	\$33,500	Emory University	Mechanisms of Antiviral Activity of TRIM-5 Alpha Protein
2008	\$105,039	Population Council	A Novel DARPins Strategy for Combating HIV
2008	\$43,054	Imperial College London	Gene Expression Microarray Analysis of NK Cell Function in the Gastro. Tract of HIV+ People
2007	\$65,700	University of Minnesota	Impact of Human APOBEC3 Proteins on HIV Drug Resistance
2007	\$80,000	University at Buffalo	Novel Assays for Antiretroviral Intra/Extracellular Measurements
2007	\$81,000	Roger Williams Medical Center	Enhancing Potency of Anti-HIV Chimeric Immune Receptors
2007	\$79,640	Beth Israel Deaconess Med Ctr	Preclinical Evaluation of Bacterially-Displayed Anti-HIV Antibodies to Prevent HIV Infection
2007	\$65,128	UCLA Medical Center	Assessment of Drug-Resistance Mutation Fitness Costs Across HIV-1 Clades
2007	\$88,000	Washington University	HIV PI-Induced Insulin Resistance: Role of SOCS-1
2007	\$59,246	Tufts University School of Medicine	Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV+ Patients
2007	\$71,973	Univ. of Massachusetts	Molecular & Biologic Properties of Transmitted HIV-1 Variants in a Mother-Child Cohort

2006	\$104,181	Albany Medical College	Mechanisms of Naturally-Occurring HIV-1 Inhibitors
2006	\$84,018	Univ. of Colorado Health Sciences Center	Alpha-1 Antitrypsin Inhibits HIV-1 (Extension funding)
2006	\$97,196	Cleveland Clinic	Analysis of Novel Mutagenic Compounds to Lead HIV to Error Catastrophe
2006	\$88,000	Univ. of Southern California	Design of Second Generation HIV-1 Integrase Inhibitors
2006	\$90,273	Univ. of California, Davis	Long-term Non-Progressor Resistance Factors
2006	\$79,200	Thomas Jefferson University	Role of Heterologous Hep C Virus RNA-Dependent RNA Polymerase in Human Cells...Enhancing RNAi Against HIV-1
2006	\$85,800	Medical College of Wisconsin	HIV Hiding in Mature Dendritic Cells Establish Viral Reservoirs
2005	\$83,981	Rush University Medical Center	Evaluating the Role of Antigen-Specific Tcells in HIV Immunity
2005	\$87,718	George Washington University	Mechanisms of Atherogenic Effect of HIV-1 Infection
2005	\$11,603	Yale University School of Medicine	CXCR4 Allosteric Agonists
2005	\$82,098	Wistar Institute	Mouse Model to Test Efficacy of HIV-1 Vaccines
2005	\$110,000	UMASS Medical School	Mechanism of HIV-1 Persistence in the Face of HAART
2005	\$160,000	CRI, New England	Randomized Controlled Trial of a Weekly Schedule of Five Days On / Two Days Off
2004	\$75,000	University of Colorado Health Sciences Center	Alpha-1 Antitrypsin Inhibits HIV-1
2004	\$60,000	University of Pittsburgh	Evaluation of Novel Antiviral Targeting HIV-1 Vpr



2004	\$40,000	Univ. of California, San Diego	Protecting Cells from HIV Infection & Destruction In Vivo
2004	\$78,650	Burnet Institute, Australia	Role of HIV Infection of Astrocytes in the Development of HIV-Ass'd Dementia
2004	\$65,100	Johns Hopkins	Targeting the HIV Macrophage Reservoir
2004	\$75,000	Aaron Diamond AIDS Research Ctr.	Inhibition of Integrase-Mediated Viral Nuclear Transport
2004	\$80,000	Mount Sinai School of Medicine	Chemical Inhibitors for the HIV Tat/PCAF Complex
2003	\$44,000	Ohio State University	Impact of Anti-AIDS Drugs & Drug Resistance on HIV Evolution
2003	\$79,200	Mass. General Hospital	HIV-1/HCV Coinfection: Role of HCV-Specific Tcells in Complicating HIV-1 Infection & Therapy
2003	\$71,500	Mass. General Hospital	Comprehensive Assessment of HIV-1 Specific CTL Responses in Infected Chinese for Vaccine Design
2003	\$75,000	Global Alliance to Immunize Against AIDS (GAIA)	GAIA AIDS Vaccine Project/Bamako, Mali
2003	\$60,000	University of Southern California	HIV Vaccine Development Utilizing a Goat Lentivirus
2003	\$25,017	The New York Blood Center	HIV-1 Entry Inhibitors Targeting Hydrophobic Cavity in gp120
2003	\$88,062	University of Miami	Longitudinal Assessment of Autologous Neutralizing Antibodies in Children Perinatally Infected w/HIV-1
2003	\$38,500	University of Southern California	Epidemiology & Clinical Significance of PCP Colonization
2003	\$75,000	University of California, San Francisco	Identification of the CD8+ Cell Anti-HIV Factor
2002	\$55,000	Univ. of Massachusetts	Determinants of Non-Progressive HIV-1 Infection in Women & Children

2002	\$75,843	Center for Blood Research	Subtype-Specific Regulation of HIV1 Gene Expression
2002	\$65,000	Rush-Presbyterian-St. Luke's Medical Center	Impact of IL-7 on HIV Infection of Naive Cells...Potential Role of IL-7 as an Immune Modulator
2002	\$96,525	CRI, New England	Maintenance HIV Suppression w/Cyclic Weekly HAART 5/2 Schedule
2002	\$103,202	Childrens Hospital Los Angeles	Bone Size & Bone Mineral Density in HIV+ Children & Adolescents
2002	\$83,113	Washington University	Extension Grant from 2001 (see above)
2002	\$32,141	New Jersey Med. School	Prevalence of Anal HPV & Anal Dysplasia in HIV Seropositive Adolescent & Young Adult Males
2002	\$79,200	Dana-Farber Cancer Inst.	Viral Determinants & Mechanisms for HIV-1 Neurotropism & CNS Pathogenesis
2001	\$72,050	Cornell University	Role of CCR-5 in Interlukin-12 Production in HIV-1 Infection
2001	\$79,200	St. Luke's-Roosevelt Hospital Center	Application of Molecular Techniques to the Study of HIV-Associated Lipodystrophy
2001	\$58,267	Georgetown University	Development of HHV-6 U94 As a Novel Anti-HIV Therapy
2001	\$87,467	Washington Univ. School of Medicine	Rosiglitazone & Exercise Training: Effects on HIV+ People w/Insulin Resistance, Hypertriglyceridemia, & Adipose Tissue Maldistribution
2001	\$77,000	Univ. of California, San Diego	Lentiviral Vectors Interfering w/CD4 Downmodulation as an HIV Anti-viral Strategy
2001	\$55,000	Univ. of California, San Francisco	Systemic Delivery of Tat and the Effects on HIV Replication and the Host
2001	\$10,000	Childrens Hope Foundation	Emergency Grant (9/11 Impact)

2001	\$50,000	Aaron Diamond AIDS Research Center	Aggressive Antiviral Therapy During Acute HIV-1 Infection
2001	\$50,072	Schneider Childrens Hospital	Siberian Ginseng: A Modulator of TH1-Like T-cell Cytokine mRNA & Cytokine Protein Expression in Pediatric HIV Infection
2000	\$25,000	The Wistar Institute	Extension Grant from 1998 (see above)
2000	\$47,850	University of Kentucky	Analysis of Antiviral Efficacy of RRI
2000	\$64,990	UCLA School of Medicine	Phase I Gene Therapy Study Using a Lentiviral Vector for Patients w/Multi-Drug Resistance to HIV
2000	\$91,707	Washington University	Characterizing Osteopenia in HIV+ People Treated w/ Protease Inhibitors
2000	\$55,000	Robert Wood Johnson Medical School	Extension Grant from 1999 (see above)
2000	\$63,000	UCLA School of Dentistry	Role of Candida Species in Endodontic Infections in HIV+/AIDS Population & Its Effect on Endo. Treatment
2000	\$26,675	University Hospitals of Cleveland	Pilot Trial to Evaluate Effect of Antioxidants in HIV+ Patients w/Lipodystrophy or Hyperlactatemia
2000	\$45,000	State University of New York	Generation of Anti-HIV Cytotoxic T-Lymphocytes Using Lentivirus Vectors
1999	\$105,686	University of Southern Cal.	Extension Grant from 1998 (see above)
1999	\$69,832	The Rockefeller University	Importance of Dendritic Cells in SIV delta nef Vaccines
1999	\$53,381	St. Louis University	Enhancement of Anti-HIV Immunity by Sequential Immunization w/Heterologous Live Virus Vectors
1999	\$85,121	Washington University	Characterizing Diabetes & Lipid Disorders in HIV+ People Treated with Protease Inhibitors

1999	\$60,500	Rush-Presbyterian-St. Luke's Med. Center	Mechanism(s) of Protection Against in utero HIV Transmission
1999	\$50,000	Robert Wood Johnson Medical School	Development of a Tat-Antagonist Therapeutic for AIDS
1999	\$74,970	Mass. General Hospital	Artificial Thymus for HIV-Induced Immunodeficiency
1999	\$30,000	Tampa Bay Research Inst.	Extension Grant from 1998 (see above)
1999	\$41,363	City of Hope, CA	Extension Grant from 1997 (see above)
1999	\$38,500	Columbia University	Silencing Harmful Genes to Prevent Disease
1998	\$65,093	Oregon Health Sciences University	Preclinical Evaluation of Anti-HIV Lipophilic Prodrugs
1998	\$58,270	Tampa Bay Research Institute	Effects of Pinecone Extract (PC6) on the Progression of Murine AIDS
1998	\$71,500	Pediatric AIDS Foundation	Pediatric CTL Responses and HIV Disease Progression
1998	\$70,590	Body Positive, Houston	Use of Anabolic Steroids, Optimum Nutrition, and Exercise Therapy for HIV+ Adult Male Patients
1998	\$65,000	CRIA, New York	Pilot Study of the Effect of Recombinant Human Growth Hormone (Serostim) in the Treatment of Truncal Obesity Associated with HIV
1998	\$75,000	INSERM, France	Extension Grant from 1997 (see above)
1998	\$100,000	The Wistar Institute	Immune Function and Anti-HIV Resistance Following HAART
1998	\$42,287	University of Kentucky	Cloning of HIV-1 Genes in Tissue Culture for Drug Screening & Engineering of Therapeutic Antibodies Against HIV-1 Tat Protein
1998	\$8,928	University of Southern Cal.	Extension Grant from 1997 (see above)

1998	\$74,439	UCLA School of Medicine	Factors Related to Appointment & Medication Non-Adherence in HIV+ Men and Women
1997	\$40,645	University of Kentucky	Effect of Folinic Acid on the Hematological Toxicity of Selected Medications Used in the Treatment of Chronic HIV
1997	\$78,969	University of Miami	Evaluation of CD8 Immunologic Recovery After Subcutaneous IL2 Administration
1997	\$45,000	Community Research Initiative, New England	CD-4 Levels That Have Risen as a Result of Initiation of Protease Inhibitor Therapy
1997	\$50,500	Community Research Initiative, Miami	Joint Study with CRI New England
1997	\$44,900	Montrose Clinic, Houston	Clinical Director for HIV Research Staff Position
1997	\$26,000	AIDS Project of the Ozarks	Provide Clinical Trial Access to HIV+ Patients in SW Missouri
1997	\$114,615	University of Southern California	Immune Responses to HIV in Humans Infected with a Novel Virus
1997	\$39,772	City of Hope, CA	Anti-HIV Activity in Herbs: A Molecular Characterization
1997	\$75,000	INSERM, France	Study of Non-Progressor HIV Patients
1996	\$8,560	Mercy Hospital, Miami	Clinical Trial of Cats Claw in Asymptomatic HIV+ Subjects
1996	\$27,500	Oregon Health Sciences University	Extension of 1995 Grant (see above)
1996	\$24,000	University of Miami	Efficacy of Pentoxifylline in the Treatment of Pruritic Papular Eruption of HIV+ Patients
1995	\$30,000	University of Miami	Treatment of Scabies with Ivermectin
1995	\$29,759	Oregon Health Sciences University	Combined Modality Approaches to Treat Retroviral Disease
1995	\$15,510	Mercy Hospital, Miami	Clinical Trial of Thalidomide in the Treatment of HIV-Associated KS

